Professional Documents
Culture Documents
FDA警告信(中国)中英文对照20220106
FDA警告信(中国)中英文对照20220106
2021 年 9 月,中国深圳某企业未按《不合格品控制程序》处理,
被 FDA 发出警告信。具体详情如下:
Warning Letter
警告信
Unimicro Medical Systems-Shenzhen Co., Ltd.
联合微创医疗器械(深圳)有限公司
January 6, 2022
2022 年 01 月 06 日
Dear Roly Lee:
We have reviewed your firm’s response in the 483 Corrective Action Plan dated
October 8, 2021, and have concluded it is not adequate. You plan to modify the Veress
Needle Quality Inspection Standard and all other quality inspection standards, train
relevant personnel of the quality and production department according to the revised
Quality Inspection Standards, and perform retrospective review for all products which
had been sold for the U.S market, to analyze if there is any quality issue or adverse
event occurred. These actions have not been completed. In addition, your firm has not
identified plans to evaluate their document control system, to make changes to ensure
the requirements are consistent across documents. To ensure conformance to the
standard across all relevant in-process acceptance activities, you should evaluate your
document control system as part of your corrective action plan.
我们已经审查了贵公司在 2021 年 10 月 8 日的 483 纠正行动计划中的回应,
并得出结论认为这是不够的。您计划修改 Veress 针头质量检验标准和所有其他质
量检验标准,根据修订后的质量检验标准培训质量和生产部门的相关人员,并对
所有已销往美国市场的产品进行回顾性审查,以分析是否有任何质量问题或不良
事件发生。这些行动尚未完成。此外,贵公司尚未确定评估其文件控制系统的计
划,以进行更改以确保各文件的要求一致。为了确保在所有相关的过程验收活动
中符合标准,您应该评估您的文件控制系统,作为纠正措施计划的一部分。
7. Failure to adequately establish and maintain procedures to ensure that DHR's
for each batch, lot, or unit are maintained to demonstrate that the device is
manufactured in accordance with the DMR, and the requirements of this part as
required by 21 CFR 820.184
7.未能充分建立和维护程序,以确保每个批次或单元的 DHR 得到维护,以
证明设备是按照 DMR 以及 21 CFR 820.184 的要求制造的
For example: Your firm was not able to provide Device History Records for their
manufactured medical devices intended and exported to the US market. Your firm was
unfamiliar with FDA regulations and requirements for manufactures to include the
DHR requirements and their Device History Record Control Procedures (Doc No.
(b)(4), Ver. (b)(4) and dated (b)(4)).
例如:贵公司无法提供拟出口至美国市场的医疗设备的设备历史记录。贵公
司不熟悉 FDA 法规和制造商要求,包括 DHR 要求及其设备历史记录控制程序
(文件编号(b)(4),版本(b)(4)和日期(b)(4))。
We have reviewed your firm’s response in the 483 Corrective Action Plan. The
adequacy of the response dated October 8, 2021, cannot be determined at this time.
You state you intend to modify their DHR control procedures based on the
requirements of 21 CFR 820.184 and perform sample inspection of (b)(4) batches of
the subject device based on the revised procedure, to confirm the integrity and
correctness of the DHRs. You also plan to train relevant personnel on design,
purchasing, quality, production, warehouse, logistics, PMC, and sales department
according to the revised procedures and your firm plans to perform a retrospective
review for all products which had been sold for the US market. These actions have not
been completed; therefore, the adequacy of these actions cannot be determined until
the activities described have been completed and documentation verifying the
successful completion of these actions are provided.
我们已经审查了贵公司在 483 纠正行动计划中的回应。目前无法确定 2021
年 10 月 8 日的回复是否充分。您表示打算根据 21 CFR 820.184 的要求修改 DHR
控制程序,并根据修改后的程序对(b)(4)批受试设备进行抽样检查,以确认
DHR 的完整性和正确性。贵公司还计划根据修订后的程序对相关人员进行设计、
采购、质量、生产、仓库、物流、PMC 和销售部门方面的培训,贵公司计划对
所有已在美国市场销售的产品进行回顾性审查。这些行动尚未完成;因此,在完
成所述活动并提供证明这些行动成功完成的文件之前,无法确定这些行动的充分
性。
8. Failure to maintain device master records (DMRs) as required by 21 CFR
820.181.
8.未能按照 21 CFR 820.181 的要求维护设备主记录(DMR)。
For example: Your firm has not maintained their Device Master Records related
to the subject device, and the personnel was unfamiliar with documents, processes,
and medical devices related to the U.S market. Additionally, the manager of the site
was not familiar with the FDA regulatory requirements to include DMRs for medical
device manufacturers.
例如:贵公司没有保存与受试设备相关的设备主记录,人员不熟悉与美国市
场相关的文件、流程和医疗设备。此外,该场所的经理不熟悉 FDA 的监管要求,
包括医疗器械制造商的 DMR。
We have reviewed your firm’s response in the 483 Corrective Action Plan. The
adequacy of the response dated October 8, 2021, cannot be determined at this time.
You plan to output DMRs according to the reorganized Device History File for all
products exported and intended for the U.S market, and to retrospectively review for
all products which have been sold for the US market, to analyze if there are any
quality issues or adverse events that have occurred. These actions have not been
completed; therefore, the adequacy of these actions cannot be determined until the
activities described have been completed and documentation verifying the successful
completion of these actions are provided.
我们已经审查了贵公司在 483 纠正行动计划中的回应。目前无法确定 2021
年 10 月 8 日的回复是否充分。您计划根据已重组的设备历史文件,为所有出口
并打算进入美国市场的产品输出 DMR,并对所有已进入美国市场的产品进行回
顾性审查,以分析是否存在任何质量问题或不良事件。这些行动尚未完成;因此,
在完成所述活动并提供证明这些行动成功完成的文件之前,无法确定这些行动的
充分性。
Given the serious nature of the violations of the Act, Veress Pneumoperitoneum
Needles manufactured by your firm are subject to refusal of admission under section
801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a
result, FDA is taking steps to refuse entry of these devices into the United States,
known as 'detention without physical examination,' until these violations are corrected.
In order to remove the devices from detention, your firm should provide a written
response to this Warning Letter as described below and correct the violations
described in this letter. We will notify you regarding the adequacy of your firm's
response(s) and the need to re-inspect your firm's facility to verify that the appropriate
corrections and/or corrective actions have been made.
鉴于违反该法案的严重性质,贵公司生产的 Veress 气腹针可能会根据该法案
第 801(a)节、《美国法典》第 21 卷第 381(a)条的规定被拒绝入境,因为它
们似乎是掺假的。因此,FDA 正在采取措施,拒绝这些设备进入美国,称为“未
经检验的扣押”,直到这些违规行为得到纠正。为了将这些装置从扣押中移除,
贵公司应按照下文所述对本警告信做出书面回复,并纠正本信中所述的违规行为。
我们将通知您贵公司的回复是否充分,以及是否需要重新检查贵公司的设施,以
验证是否已采取适当的纠正和纠正措施。
Other federal agencies may take your compliance with the FD&C Act and its
implementing regulations into account when considering the award of federal
contracts. Additionally, should FDA determine that you have Quality System
regulation violations that are reasonably related to premarket approval applications for
Class III devices, such devices will not be approved until the violations have been
addressed.
在考虑授予联邦合同时,其他联邦机构可能会考虑您是否遵守 FD&C 法案
及其实施条例。此外,如果 FDA 确定您存在与 III 类器械上市前批准申请合理相
关的违反质量体系法规的行为,在违规行为得到解决之前,此类器械将不会获得
批准。
Please notify this office in writing, within fifteen business days from the date you
receive this letter, of the specific steps your firm has taken to correct the noted
violations, as well as an explanation of how your firm plans to prevent these
violations, or similar violations, from occurring again. Include documentation of the
corrections and/or corrective actions (which must address systemic problems) that
your firm has taken. If your firm's planned corrections and/or corrective actions will
occur over time, please include a timetable for implementation of those activities. If
corrections and/or corrective actions cannot be completed within fifteen business days,
state the reason for the delay and the time within which these activities will be
completed.
请在收到本函之日起十五个工作日内书面通知本办公室,说明贵公司为纠正
上述违规行为而采取的具体措施,并说明贵公司计划如何防止此类违规行为或类
似违规行为再次发生。包括贵公司已采取的纠正和纠正措施(必须解决系统性问
题)的文件。如果贵公司计划的纠正和纠正措施将随着时间的推移而发生,请提
供实施这些活动的时间表。如果纠正和纠正措施无法在 15 个工作日内完成,请
说明延迟的原因以及完成这些活动的时间。
Your firm's response should be comprehensive and address all violations
included in this Warning Letter. If you believe that your products are not in violation
of the FD&C Act, include your reasoning and any supporting information for our
consideration as part of your response. Please provide a translation of documentation
not in English to facilitate our review.
贵公司的回复应全面,包括处理本警告信中包含的所有违规行为。如果您认
为您的产品没有违反 FD&C 法案,请将您的理由和任何支持信息作为您回复的
一部分,供我们考虑。请提供非英语文件的翻译,以便于我们审查。
Your firm's response should be sent to
CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:
Refer to CMS case #424228 when replying. If you have any questions about the
contents of this letter, please contact: OHT Assistant Director, Jason Roberts at
jason.roberts@fda.hhs.gov or (240)402-6400
Finally, you should know that this letter is not intended to be an all-inclusive list
of the violations at your firm's facility. It is your firm's responsibility to ensure
compliance with applicable laws and regulations administered by FDA. The specific
violations noted in this letter and in the Inspectional Observations, FDA 483, issued at
the close of the inspection may be symptomatic of serious problems in your firm's
manufacturing and quality management systems. Your firm should investigate and
determine the causes of the violations, and take prompt actions to correct the
violations and bring the products into compliance.
最后,您应该知道,这封信并没有列出贵公司工厂的所有违规行为。贵公司
有责任确保遵守 FDA 管理的适用法律法规。本函和检查结束时发布的 FDA 483
检查意见中指出的具体违规行为可能是贵公司制造和质量管理体系存在严重问
题的征兆。贵公司应调查并确定违规原因,并立即采取措施纠正违规行为,使产
品符合规定。
Sincerely Yours,
/S/
Courtney H. Lias, Ph.D.
Office Director
OHT3: Office of GastroRenal, ObGyn,
General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
CC:
Zeyu Chen
238 Fernwood Ave, Edison, NEW JERSEY 08837